Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALPN
CUSIPN/A
Phone206-788-4545
Debt
Debt-to-Equity Ratio0.05
Current Ratio20.99
Quick Ratio20.99
Price-To-Earnings
Trailing P/E Ratio-4.81
Forward P/E Ratio-2.84
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.73 million
Price / Sales45.63
Cash FlowN/A
Price / CashN/A
Book Value$5.68 per share
Price / Book1.00
Profitability
EPS (Most Recent Fiscal Year)($1.20)
Net Income$-7,780,000.00
Net Margins-1,602.19%
Return on Equity-26.00%
Return on Assets-23.83%
Miscellaneous
Employees38
Outstanding Shares13,850,000
Market Cap$80.03 million
Alpine Immune Sciences (NASDAQ:ALPN) Frequently Asked Questions
What is Alpine Immune Sciences' stock symbol?
Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."
How were Alpine Immune Sciences' earnings last quarter?
Alpine Immune Sciences Inc (NASDAQ:ALPN) issued its earnings results on Monday, May, 14th. The biotechnology company reported ($0.38) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.40) by $0.01. The biotechnology company had revenue of $0.32 million for the quarter, compared to analysts' expectations of $0.13 million. Alpine Immune Sciences had a negative net margin of 1,602.19% and a negative return on equity of 26.00%. View Alpine Immune Sciences' Earnings History.
When is Alpine Immune Sciences' next earnings date?
What price target have analysts set for ALPN?
4 equities research analysts have issued 1-year price objectives for Alpine Immune Sciences' shares. Their predictions range from $13.00 to $13.00. On average, they anticipate Alpine Immune Sciences' share price to reach $13.00 in the next year. This suggests a possible upside of 128.1% from the stock's current price. View Analyst Price Targets for Alpine Immune Sciences.
What is the consensus analysts' recommendation for Alpine Immune Sciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alpine Immune Sciences.
Who are some of Alpine Immune Sciences' key competitors?
Some companies that are related to Alpine Immune Sciences include Sienna Biopharmaceuticals (SNNA), Clementia Pharmaceuticals (CMTA), Avid Bioservices (CDMO), Innate Pharma (IPHYF), Kala Pharmaceuticals (KALA), resTORbio (TORC), Catalyst Pharmaceuticals (CPRX), BIOFRONTERA AG/ADR (BFRA), Selecta Biosciences (SELB), Bellicum Pharmaceuticals (BLCM), Mersana Therapeutics (MRSN), Acer Therapeutics (ACER), Corvus Pharmaceuticals (CRVS), Corbus Pharmaceuticals (CRBP) and AVEO Pharmaceuticals (AVEO).
Who are Alpine Immune Sciences' key executives?
Alpine Immune Sciences' management team includes the folowing people:
- Dr. Mitchell H. Gold, Exec. Chairman & CEO (Age 50)
- Dr. Jay R. Venkatesan M.D., Ph.D., Pres and Director (Age 46)
- Dr. Stanford Peng M.D., Ph.D., Exec. VP of R&D and Chief Medical Officer (Age 47)
- Mr. Paul Rickey, Sr. VP & CFO (Age 39)
- Dr. Kristine Swiderek Ph.D., Sr. VP of Research
Has Alpine Immune Sciences been receiving favorable news coverage?
News stories about ALPN stock have been trending positive on Tuesday, Accern Sentiment reports. Accern identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alpine Immune Sciences earned a media and rumor sentiment score of 0.41 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 47.78 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Alpine Immune Sciences.
Who are Alpine Immune Sciences' major shareholders?
Alpine Immune Sciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.88%), Dimensional Fund Advisors LP (0.24%) and DRW Securities LLC (0.18%). Company insiders that own Alpine Immune Sciences stock include Bvf Partners L P/Il, David Malcom Rodman, Janice Troha, R Michael Carruthers, Robert E Conway and Value Fund L P Biotechnology. View Institutional Ownership Trends for Alpine Immune Sciences.
Which institutional investors are buying Alpine Immune Sciences stock?
ALPN stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Dimensional Fund Advisors LP and DRW Securities LLC. Company insiders that have bought Alpine Immune Sciences stock in the last two years include Bvf Partners L P/Il, Janice Troha, R Michael Carruthers, Robert E Conway and Value Fund L P Biotechnology. View Insider Buying and Selling for Alpine Immune Sciences.
How do I buy shares of Alpine Immune Sciences?
Shares of ALPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alpine Immune Sciences' stock price today?
One share of ALPN stock can currently be purchased for approximately $5.70.
How big of a company is Alpine Immune Sciences?
Alpine Immune Sciences has a market capitalization of $80.03 million and generates $1.73 million in revenue each year. The biotechnology company earns $-7,780,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Alpine Immune Sciences employs 38 workers across the globe.
How can I contact Alpine Immune Sciences?
Alpine Immune Sciences' mailing address is 201 Elliott Avenue West Suite 230, Seattle WA, 98119. The biotechnology company can be reached via phone at 206-788-4545 or via email at [email protected]
MarketBeat Community Rating for Alpine Immune Sciences (NASDAQ ALPN)
MarketBeat's community ratings are surveys of what our community members think about Alpine Immune Sciences and other stocks. Vote "Outperform" if you believe ALPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
